Chapter 29: Drugs for Headache Disorders

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to the Deep Dive.

We are trying something a little different today.

We're calling this the Last Minute Lecture Session.

It's, you know, for everyone out there who maybe has a pharmacological showdown coming up or for those who just want to understand the machinery of their own bodies a little bit better.

I love the urgency of that title.

It suggests we need to get down to business.

We absolutely do because today we are tackling, well, a beast of a chapter.

We really are.

We are opening up Brenner and Stevens Pharmacology, specifically chapter 29.

The title is Deceptively Simple, Drugs for Headache Disorders.

Deceptively, yes.

But once you actually crack the binding and look at the text, you realize, okay, this is not just about popping an ibuprofen and taking a nap.

This is heavy -duty neurobiology.

It really is.

And it's a fascinating chapter because it bridges this gap between ancient medicine,

literally fungi growing on grain,

and the absolute cutting edge of biotechnology with monoclonal antibodies.

So our mission today is to walk through this chapter exactly as it's presented in the text.

No outside noise.

None.

We're going to decode the science.

We'll translate the tables and make sense of the diagrams so that you, the listener, can walk away feeling like you've actually mastered this material.

And the hook here is pretty obvious.

I mean, everyone knows what a headache feels like.

The text actually opens with that framing, doesn't it?

It does.

It says for the vast majority of people, a headache is just a nuisance.

You know, it's a signal to drink some water, take a break, maybe pop an aspirin.

But then the text pivots hard.

Right.

It pivots to the 24 million Americans for whom taking aspirin is, well, it's essentially an insult.

Yeah.

We're talking about migraine disorders.

Yeah.

And the text defines this, not just as pain, but as a complex neurovascular event.

It's a storm in the brain.

A storm in the brain.

I like that.

So here's how we're going to navigate this deep dive.

We're just going to follow the logic of the biology itself.

We'll start with the why, the pathogenesis.

Why does the head hurt?

Then we'll look at the case study presented in the text, which I think is a perfect anchor for the rest of the discussion.

It really is.

And that will naturally lead us into the two main battle strategies, prevention and termination.

Exactly.

Stopping the storm before it clouds over versus fighting the storm while you're in the middle of it.

A huge distinction.

So let's get into the physiology.

The text kicks off with a classification system.

And if you're following along in the book, you can see table 29 .1, which breaks headache disorders into two massive buckets.

Primary and secondary.

And this seems like a vital distinction to make right out of the gate.

It's probably the most important fork in the road.

Secondary headache disorders are symptoms.

They're symptoms of an underlying organic disease.

Okay.

So what kind of diseases are we talking about?

Well, the text lists things like a hemorrhage, an infection, a stroke, or a tumor.

In these cases, the headache is just the alarm bell.

Right.

You don't treat the alarm.

You treat the fire.

You treat the fire.

You treat the infection or the tumor.

If you have a brain tumor, taking a migraine pill is not only ineffective, it's dangerous because it ignores the root cause.

Precisely.

But the chapter and our discussion today, it really focuses on that primary group.

This is where the headache is the disorder.

This is the 95%.

This is the 95 % of all cases.

It includes cluster headaches, tension headaches, and the big one that really dominates the pharmacology text,

migraines.

Okay.

So let's zoom in on the migraine.

The text uses a phrase that I really want to unpack because honestly, it sounds terrifying.

Neurovascular dysfunction.

It does sound intense, but if you break the words down, it tells the whole story.

Neuro, referring to the nerves.

And vascular for the blood vessel.

Exactly.

So the dysfunction is a glitch in how they talk to each other.

The text explains it as an imbalance between excitatory and inhibitory neuromal activity.

So it's like my brain's wiring is off.

Think of your brain like a high -performance car.

You have the gas and you have the brake.

In a migraine brain, the calibration is just off.

The system is too sensitive.

And that calibration gets thrown off by triggers.

The text gives a whole laundry list of them.

A long list.

Hormones, stress, fatigue, hunger, diet, even other drugs.

All these things can kick off this chain reaction.

Right.

And for about 15 % of patients, that reaction starts with something called an aura.

Now the text gives these clinical descriptions, but I want to really paint the picture of what the text is actually describing here.

Please do because the term Tychopsia is thrown out there and that is not a word you hear in federal conversation.

No, it is not.

So imagine you're sitting at your desk, you're looking at your computer screen, and suddenly in the corner of your vision, you see a flickering light.

Okay.

It's not a light in the room.

It's a jagged, shimmering fortress of light that starts to expand.

It ripples like heat coming off hot pavement.

That is Tychopsia.

Wow.

And that's a hallucination?

It's a visual hallucination, yeah.

Caused by the brain's electrical activity just going haywire.

The text mentions, it's not just visual though, there's a sensory component that sounds even more unsettling,

the marching sensation.

Yes, the peristhesias.

This is that pins and needles feeling you get when your foot falls asleep, but in an aura,

it moves, it migrates.

What do you mean it moves?

It might start in your fingertips, then over the course of maybe 15, 20 minutes, it marches up your hand, up your arm, and then it settles into your face and your tongue.

That's incredibly specific.

And physically, biologically, what is happening in the brain during those 15 to 20 minutes of the aura?

So the prevailing theory that the text presents is that this is caused by cerebral vasoconstriction and ischemia.

Okay, let's break that down.

Vasoconstriction.

The blood vessels in specific parts of the brain are clamping down.

They're getting really tight.

And ischemia.

That's the result.

The tightening restricts blood flow.

And that lack of blood flow is the ischemia.

And that lack of oxygen and fuel causes those neurons to misfire, giving you the lights and tingling.

Okay, so the aura is phase one.

A lack of blood flow.

Well, it's the prelude.

It leads us directly into the timeline of the attack itself.

And the text breaks that down into two distinct phases.

Phase one is exactly what we just described.

The squeeze.

Correct.

Phase one is the vasoconstriction and ischemia phase.

And the text identifies a very specific chemical culprit here.

Which is?

Serotonin.

Now, this is where listeners might get confused because we usually think of mood, yes.

But in the context of vascular biology,

serotonin is a potent vasoconstrictor.

It's a squeezer.

I see.

During phase one, the text explains there is a massive release of serotonin from both central nervous system neurons and from circulating platelets.

It's like a serotonin dump.

This chemical flood is what causes the vessels to clamp down.

Okay, so phase one is the squeeze.

The blood flow is low.

But a migraine isn't usually described as a tight squeezing feeling.

It's almost always described as a throbbing, pounding pain.

So how do we get from the squeeze to the pounding?

That is phase two.

And it's a perfect question.

The text calls this the vasodilation and pain phase.

Think of it as a rebound effect.

A pendulum swing.

Okay.

The serotonin levels drop.

And the vessels don't just return to normal.

They swing all the way to the other extreme.

They swell up.

But wait, vasodilation happens when I go for a run or sit in a sauna, and I don't get a migraine.

So why is this different?

What's the missing piece?

The missing piece is inflammation.

Because this isn't just plumbing.

It's a full blown inflammatory event.

And this is where we have to look at figure 29 .1 in the text, which illustrates the trigeminal connection.

Okay.

This figure is key to understanding everything that follows regarding the drugs.

So walk us through that diagram.

We've got the trigeminal nerve, which is the big nerve responsible for sensation in the face and head.

Right.

So in phase two, as the vessels are dilating, neurons in the trigeminal complex start dumping these things called visoactive peptides.

And the text highlights two specific bad actors.

It does.

Substance P and CGRP.

CGRP, calcitonin gene related peptide.

I feel like we should put a big red pin in that acronym because it is going to become the crucial.

So you have these peptide substance P and CGRP flooding the area around the pile and dural vessels.

Those are the blood vessels covering the brain.

And these peptides cause two things,

massive dilation, even more than just the rebound effect and something called neurogenic inflammation.

The vessels become swollen, leaky and inflamed.

And that inflammation is what stimulates the pain fibers.

It stimulates the nociceptors, the pain fibers of the trigeminal nerve.

So the throbbing pain is literally the sensation of blood pumping through these swollen inflamed vessels, triggering the nerve with every single beat of the heart.

Exactly.

That's it.

It's a mechanical and a chemical assault on the pain system.

That's a fantastic explanation.

So to recap the biology before we move on, phase one is a serotonin driven squeeze.

Phase two is a peptide driven swelling inflammation.

You got it.

That sets the stage perfectly.

We know the enemy mechanisms now.

Before we start throwing drugs at these mechanisms, I want to look at the case study in box 29 .1.

Yeah.

The text introduces us to a patient and her story really illustrates the clinical reality of all this.

It really does.

It's the case of the unmitigating migraine.

Sounds ominous.

It is.

We have a 26 year old woman.

She has a history of migraines and she's been doing what many patients do, taking Sumitriptan whenever an attack starts.

That's a triptan, one of the standard abortive drugs.

A very common one, but she ends up in her doctor's office because the Sumitriptan isn't working anymore.

The attacks are getting more frequent and the drug is failing her.

This is a classic narrative in headache medicine, isn't it?

It's a very common story.

The physician reviews her file and sees the pattern.

She's using the abortive medication way too often.

So the diagnosis?

The diagnosis is tolerance or a loss of effectiveness due to overuse.

Her brain has literally adapted to the drug.

It's learned to expect it.

So the doctor has to pivot and this pivot is what structures the rest of our discussion.

He doesn't just give her a stronger painkiller.

No, that would make it worse.

He changes the entire strategy.

Ah, so.

He puts her on a two pronged approach.

First, he prescribes Valprodid.

This is for prophylaxis or prevention.

The goal is to stop the attacks from ever happening in the first place.

Okay, so that's the long game.

That's the long game.

Second, he switches her rescue medication from Sumitriptan to intranasal dihydroergotamine or DAG to treat the acute attacks when they do break through.

And that distinction, prevention versus termination, is the scaffolding for the rest of this entire chapter.

It really is.

So let's start where the doctor started.

Prevention.

The prophylactic strategy.

The mindset here is totally different.

The text explains that prophylactic drugs are taken every single day, regardless of how you feel.

Even on good days.

Especially on good days.

The goal is to prevent that initial vasoconstrictive phase, that phase one squeeze, from ever getting started.

And the text really emphasizes that this is not a quick fix.

No, it is a slow burn.

The text explicitly warns that it requires weeks of therapy, often they say four to six weeks, before the patient sees any real benefit.

It requires patience, which is, you know, really hard when you're in pain.

Absolutely.

So let's walk through the drug classes used for prevention, exactly as they're laid out.

The first one mentioned in the text is the one our case study patient was prescribed.

Anti -epileptic drugs, or AEDs.

Specifically, Velprote, which has the brand name Depakine.

Now, you might ask, why on earth are we giving an epilepsy drug to a migraine patient?

That was my next question.

It goes back to that neurovascular dysfunction.

Migraine, like epilepsy, is at its core a disorder of hyper -excitability.

The neurons are just firing too easily.

The gas pedal is too sensitive.

Exactly.

Velprote stabilizes those neurons.

It essentially raises the threshold for what it takes to start that electrical storm.

But as with all these drugs, there is a cost.

The text is very clear about the adverse effects.

Right.

It lists sedation, tremor, and weight gain.

These are not trivial side effects, especially for a young person.

It is always a trade -off.

Okay, so that's AEDs.

The next class for prevention is antidepressants.

This seems to be a recurring theme in pharmacology drugs from one field to treat another.

It is, and for good reason.

The text discusses a few types, mainly the tricyclic antidepressants, or TCAs, and the SSRIs.

But the mechanism here is really fascinating.

It's not just about mood.

Not directly.

It's about receptor regulation.

The text explains that chronic use of these antidepressants leads to a down regulation of postsynaptic serotonin receptors.

Let's translate down regulation.

What does that mean in plain English?

Think of it like a thermostat in your house.

If the house is always too cold, meaning there's low serotonin activity, the heater works over time, and the whole system becomes hypersensitive to any change.

Okay.

By using these drugs, we're essentially recalibrating that thermostat.

Over time, the brain says, okay, there's enough serotonin signaling here.

I don't need to be so jumpy.

It causes a compensatory stabilization in neuron firing.

The text makes a specific chemical distinction here regarding the tricyclics.

It says tertiary amines are better than secondary amines.

It does.

And this is a high yield point.

Amitriptyline is the prime example of a tertiary amine.

The text notes it's a more potent inhibitor of serotonin reuptake than the secondary amines are.

So it's simply more effective for migraine prevention.

And then there are the MAOIs, like phenylzine.

But the text seems to treat these like the nuclear option.

They are absolutely the last resort.

MAOIs work by blocking the enzyme that degrades serotonin, so they boost levels very significantly.

Sounds good.

But the dietary restrictions are brutal.

The text specifically mentions the tiramine interaction.

Tiramine is an amino acid found in things like aged cheese, cured meats, red wine.

All the good stuff.

Pretty much.

And if you eat those foods well on an MAOI, you can trigger a hypertensive crisis, which is a stroke level blood pressure spike.

So compliance is a huge issue.

Okay, moving on to a drug class that is usually associated with heart health, beta blockers.

Right, the beta adrenoceptor antagonist.

This is a first line therapy for many patients.

But there's a very specific high yield rule in the text here that you have to know.

What's the role?

It says only beta blockers lacking intrinsic sympathomimetic activity are effective.

That is a mouthful.

Intrinsic sympathomimetic activity or ISO.

Let's break it down.

Some beta blockers are pure blockers.

They sit on the receptor and do nothing but block it from being activated.

Others, the ones with IDESA, sit on the receptor and block it.

But they also

tickle it a little bit.

They have a slight stimulating effect at their own.

And that's bad for migraines.

The text is clear.

If the drug has that tickle, that ISA, it does not work for migraine prevention.

You need a pure blocker like propranolol or timolol.

And the theory on how they work.

There are a couple.

The main one is that by blocking beta 2 receptors, they attenuate that phase 2 vasodilation, preventing the vessels from blowing up and getting inflamed.

Makes sense.

Okay, now let's talk about the newest kids on the block for prevention.

The CGRP -targeted monoclonal antibodies.

This feels like the part of the chapter where the sci -fi music should start playing.

It really is a massive leap forward.

Remember earlier we talked about CGRP, that peptide released by the trigeminal nerve that causes all the pain and inflammation.

The star of the show.

The villain of the show, maybe.

For decades, we knew it was the bad guy, but we couldn't really stop it.

Now we have these bioengineered antibodies that act like guided missiles.

And the text describes two distinct ways these missiles work, right?

Two different strategies.

Exactly.

Strategy one is to shoot the bullet out of the air.

Drugs like alkanazumab, which is mGallity, and fermioniazumab, they bind directly to the CGRP molecule that's floating in the blood.

So they neutralize it.

They neutralize it before it can ever reach its target and do any damage.

And strategy two.

Strategy two is to block the bulletproof vest.

So a drug like erinumab, which is amovig, it doesn't touch the CGRP molecule.

Instead it binds to the CGRP receptor on the blood vessel.

So the CGRP is still floating around.

But it has nowhere to dock.

It's like putting gum in the keyhole.

The signal can't get through.

And because these are antibodies, these huge proteins, you can't just take them as a pill.

No, your stomach would just digest them like a piece of steak.

They have to be injected.

Galcanazumab is a monthly subcutaneous injection.

Fremontazumab is quarterly.

It's a huge shift in treatment from taking a daily pill like a beta blocker.

Definitely.

There is one more prevention agent mention that I have to bring up because it's just so famous in pop culture.

Botox.

Botox.

Botulinum toxin A.

Yes, the text includes it as an approved treatment specifically for chronic migraine.

And its mechanism is really interesting.

It works by disrupting acetylcholine transmission at the nerve ending.

How does it do that?

It prevents the vesicles that hold the neurotransmitter from fusing with the cell membrane.

So it essentially silences the nerve.

It stops the conversation between the nerve and muscle or the blood vessel.

So that covers the long game prevention.

A lot of options there, but what if prevention fails?

Or what if you aren't on preventative meds?

You wake up, the aura starts, the pain hits.

We need to terminate the attack.

This brings us to section four in the text, drugs for migraine termination.

The abortive strategy.

And the strategy here just completely flips.

In prevention, we were trying to stop the initial squeeze.

In termination, we are deep in phase two, the vasodilation.

The vessels are swollen and painful.

They are swollen and painful.

We need to constrict them.

We need to reverse the flow.

And to do that, we focus almost entirely on serotonin 5 -HT1 agonists.

Okay.

We need to do a receptor deep dive here because the text throws around a lot of numbers like 5 -HT1, 5 -HT2.

Why does the number matter?

Why can't we just say serotonin receptor?

Because the body is incredibly specific.

Serotonin does a hundred different things in a hundred different places through different receptor subtypes.

It's not So what's the difference here?

The text clarifies this beautifully.

5 -HT2 receptors are the ones that mediate that initial vasoconstriction and platelet aggregation, the bad stuff in phase one.

So for prevention, some older drugs used to block those.

Okay.

So 5 -HT2 is bad in phase one.

Right.

But for termination, we want to activate or agonize the 5 -HT1 receptors.

Why 5 -HT1 specifically?

Because they are predominant in the central nervous system and on the cranial blood vessels.

Activating the 5 -HT1 receptor does three magical things for a person with a migraine.

Okay.

What are they?

One, it constricts those swollen painful pile and dural vessels.

It brings them back to size.

The reverse squeeze.

The reverse squeeze.

Two,

it inhibits the release of those nasty peptides like CGRP from the trigeminal nerve endings.

So it stops the inflammation at the source.

It does.

And three, it interrupts pain transmission in the brainstem itself.

It basically hits the mute button on the pain signal.

That's a powerful combination.

It's the trifecta.

And the first class of drugs discovered to do this has one of the wildest backstories in all of pharmacology.

The ergod agents.

The old guard.

The classics.

The history here is incredible.

The text mentions that ergod refers to the product of a fungus, claviceps purpurea, which grows on rye grain.

In the middle ages, people would eat infected rye bread and they would get something called St.

Anthony's fire.

Which was gangrene, right?

From the vasoconstriction.

Yes.

The vasoconstriction caused by the fungus was so potent that blood flow would get cut off to the extremities and people's fingers, toes, their limbs would literally turn black and fall off.

It was horrific.

How does something that horrific become a medicine?

Because pharmacology is all about the dose.

Scientists realized that if you took those same

but controlled the dose very carefully, you could use that powerful vasoconstriction to treat a throbbing headache.

That is a terrifying origin story for a medicine.

It really is.

And as a bit of trivia, the text notes that LSD is actually an ergod derivative.

Albert Hoffman was studying ergod compounds for headaches and circulation when he accidentally discovered LSD psychedelic properties.

Wow.

But clinically for headaches, we use ergodamine and dihydro ergodamine or DHE.

Correct.

And the text describes these as dirty drugs.

That sounds judgmental.

What does that mean pharmacologically?

It's pharmacological slang.

It means they aren't selective.

They hit the 5 -HT1 receptors we want them to, but they also hit dopamine receptors, arginergic receptors, and a bunch of others.

So like a shotgun blast.

A shotgun blast.

Exactly.

They just spray the whole area.

Because of that shotgun blast, the side effects are rough.

Nausea is the big one.

Ergodamine stimulates the chemoreceptor trigger zone in the brain, which is basically the vomit center.

Which is so ironic.

It's deeply ironic.

The text points this out.

Migraines cause nausea.

And the drug to treat it can cause even more nausea.

That's why DHE is often given with an anti -nausea medication like metoclopramide.

And the administration of these is unique, to say the least.

Well, yeah.

Ergodamine has terrible oral bioavailability.

Your liver just chews it up.

So the text mentions it's often given as a rectal suppository.

Which, again, if you're already nauseous and in agonizing pain, that does not sound ideal.

It is not ideal.

That's why DHE, which comes as a nasal spray or an injection, is often preferred.

But the biggest safety warning in the text regarding ergots goes right back to St.

Anthony's Fire.

The vasoconstriction.

You absolutely cannot use these in patients with coronary artery disease.

If you clamp down on a heart vessel that is already narrowed by plaque, you can cause a heart attack.

Same goes for peripheral vascular disease.

Okay.

So because ergots were dirty and dangerous for the heart, scientists went hunting for a cleaner version, a more targeted approach.

And that gave us the triptans.

Enter sumatriptan.

This was the absolute revolution of the 1990s in headache medicine.

Triptans are structural analogs of serotonin itself.

They were designed in a lab to fit into the lock perfectly.

And which lock is that?

They are highly selective for the 5 -HT1D and 1 -B receptors.

So they are snipers instead of shotguns.

Exactly.

They hit the receptors, they constrict the brain vessels and stop the peptide release, but they ignore all the dopamine and other receptors that the ergots hit.

This makes them much, much more tolerable for most people.

But are they perfect?

The text seems to suggest there are still some issues.

It compares sumatriptan to DHE.

Right.

So in a head -to -head comparison, subcutaneous sumatriptan, the injection, is faster.

The text says it brings relief in about an hour for up to 85 % of patients, which is amazing, but it could wear off.

The recurrence rate.

It highlights a high recurrence rate.

About 40 % of patients have the headache come roaring back later that same day.

It's this frustrating roller coaster effect.

And what about safety?

They're cleaner than ergots, but are they perfectly safe for the heart?

No.

And this is a critical point.

While they are cleaner, they are not perfectly safe.

The text describes a very specific side effect.

Chest tightness.

That sounds alarming.

It is.

It happens in up to 50 % of users.

It feels like a heavy weight on the chest.

And of course, it mimics a heart attack, which causes a lot of panic.

Isn't a heart attack?

The text says this feeling is likely due to constriction of esophageal muscles or bronchoconstriction in the lungs, not necessarily the heart.

However, and this is a big hell ever,

tryptans still cause coronary vasospasm.

Why?

Because the 5 -HT1B receptor, one of their main targets, is also found on coronary arteries.

So just like ergots, you cannot give tryptans to patients with angina or history of heart attack.

So we have the dirty drugs, the ergots and the sniper drugs, the tryptans, but both are potentially dangerous for the heart.

This brings us to the new generation mentioned in the text.

Is there finally a heart -safe option?

Yes.

This is the breakthrough of a drug called lasmititan, brand name Rayval.

How does it pull that magic trick on, how does it avoid the heart issue?

By getting even more specific with the receptor.

Lasmititan was designed to target the 5 -HT1F receptor.

Note the F at the end.

It does not hit the B receptor that's on the blood vessels.

Okay, so what does the F receptor do?

The 5 -HT1F receptor is located on the trigeminal nerve itself.

So lasmititan works by inhibiting the pain pathways in the nerve without causing any vasoconstriction.

It turns off the pain alarm without clamping down on the pipe.

That is huge.

It is.

It means for the first time, we have a powerful serotonin -based migraine drug that is safe for cardiac patients.

But there's a catch, right?

There's always a catch.

The catch is CNS suppression.

Because it works so heavily in the brain stem and central nervous system, it causes significant dizziness and sedation.

The text is very clear that you should not drive for at least 8 hours after taking it.

Okay.

Also in this new generation, the text mentions the oral capense.

Yes.

UbrogePant, which is Ubrelvi, and RumigiPant, which is Nurtek.

And how do they work?

These act just like the CGRP antibodies we talked about for prevention.

They block the CGRP receptor, but they are small molecules.

You can swallow them as a pill to stop an attack that's already started.

So you get the benefit of that targeted CGRP blockade, but without needing a needle.

Exactly.

The main side effect listed is nausea, but they are generally very well tolerated.

Before we wrap up the drugs, there is a kind of rapid fire section in the text on other agents.

Can we just quickly touch on those?

Yeah, let's do it.

First, antisides like naproxen.

They can work for mild to moderate attacks.

Okay.

Then there are opioids like tramadol and a nasal spray called butorfenol.

But the text is very, very cautious here.

These are reserved for severe resistant cases only because of the high risk of addiction and overuse.

Of course.

Then, interestingly, prochlorperazine, which is actually an anti -psychotic and anti -nausea drug -given IV in the emergency room, is mentioned as a powerful way to break a severe unremitting migraine.

Fascinating.

So we have covered the drugs, now we need to cover the rules.

Section 5 in the text is on guidelines, and it discusses the rule of limits.

This is critical for any student to know and for any patient to understand.

You cannot just pop these abortive pills like candy.

Why not?

If you overuse them, you get something called rebound headache or medication overuse headache.

The headache actually comes back because the brain becomes dependent on the drug to keep the vessels regulated.

You're treating the headache with the cause of your next headache.

It's a vicious cycle.

So what are the hard limits laid out in the text?

For ergots,

a maximum of 8 days per month.

For triptans,

a maximum of 6 days per month, and the text recommends no more than 2 days per week.

And opioids.

Even stricter.

Maximum of 2 days per week.

The rule of thumb is if you find yourself needing these abortive meds more often than that, you need to be on a preventative medication.

You're losing the war.

That's a very clear line in the sand.

Okay, finally, let's briefly distinguish the other two primary headaches mentioned in the chapter.

First, cluster headaches.

How do I know if I have this and not a migraine?

The behavior of the patient is the biggest tell.

The text paints a really vivid picture.

A migraine patient wants to lie perfectly still in a dark, quiet room.

Any movement, any light, any sound is agony.

A cluster headache patient paces.

They are intensely agitated.

The pain is described as searing or burning, usually right behind one eye.

It is so severe, it's often called suicide headache, that the patient rocks back and forth.

They pace the room.

Some even strike their own face to create a counter pain.

It is always, always unilateral.

That sounds absolutely brutal.

The treatment has to be different, right?

Totally different because the attack is relatively short, maybe 15 minutes to three hours, but incredibly intense.

Pills are just too slow to work.

So what does work?

For termination, the text recommends 100 % oxygen inhalation through a mask or intranasal lidocaine to numb the nerves.

For prevention, it's very different from migraine.

The mainstays are lithium and the calcium channel blocker verapamil.

And lastly, tension headaches.

This is the normal headache most of us get.

Right.

The text describes this as a band -like pressure around the head, like a tight hat.

It is bilateral, meaning on both sides, and it's non -pulsatile.

It doesn't throb.

And the treatment is much simpler.

Much simpler.

Physiologic things like correcting your posture or getting your vision checked, plus NSAIDs and muscle relaxants.

For chronic cases, the text mentions amitryptaline can be used for prevention.

We have unpacked the entire chapter.

I mean, from the serotonin squeeze.

It's the peptide swell.

From the moldy rye bread of the Middle Ages.

To the bioengineered antibodies of today.

It's an incredible journey.

It really is.

I want to leave the listener with a final thought here.

We spend so much time in pharmacology memorizing names.

Sumitriptan, galcanazumab, agotamine.

It can feel like just a list.

But if you step back, this chapter is really a story about how we are slowly, piece by piece, mapping the geography of human suffering.

That's a beautiful way to put it.

We started with, it hurts.

Let's eat this fungus from a piece of bread.

Then we move to, it hurts.

Let's design a molecule that mimics this other molecule.

And now we're at, it hurts.

Let's create an antibody to block this specific genetic peptide.

It just makes you wonder what's next.

That's the question, isn't it?

Are we going to find the master switch?

Or is the brain always going to be a little bit more complex, a little bit faster than our chemistry?

I think that is the ultimate question in neuropharmacology.

The brain is so complex.

And as we saw with the redundancy in these pain systems, it often finds a way to bypass our blockades.

But the progress, as this chapter shows, is just undeniable.

It certainly is.

Well, that's it for this last -minute lecture and deep dive into Brenner and Stevens chapter 29.

We really hope this helps you navigate the dense world of headache pharmacology.

And don't forget to look at those dosage tables in the book.

We explain the how, but the how much is always in the fine print.

Thanks for listening.

We'll see you in the next deep dive.

Stay curious.